Murine and Human Lupus Nephritis: Pathogenic Mechanisms and Theoretical Strategies for Therapy

Seminars in Nephrology

Volumn 35, Issue 5, 2015, Pages 427-438

  Pedersen, Hege Lynum ^a   Horvei, Kjersti Daae ^a   Thiyagarajan, Dhivya ^a   Seredkina, Natalya ^a   Rekvig, Ole Petter ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Chaperone molecules; DNase I; Heparin; Murine human lupus nephritis; Systemic lupus erythematosus; Therapeutic strategies

Indexed keywords

CHAPERONE; DEOXYRIBONUCLEASE I; DOUBLE STRANDED DNA ANTIBODY; GELATINASE A; HEPARIN; NUCLEOSOME ANTIBODY; ANTINUCLEAR ANTIBODY; CHROMATIN; FIBRINOLYTIC AGENT; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MATRIX METALLOPROTEINASE;

ARTICLE; CHROMATIN; DNASE I GENE; ENZYME DEGRADATION; GENE SILENCING; GLOMERULUS BASEMENT MEMBRANE; HUMAN; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; CROSS REACTION; DISEASE MODEL; GENETICS; GLOMERULUS; IMMUNOLOGY; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE;

ANIMALS; ANTIBODIES, ANTINUCLEAR; CHROMATIN; CROSS REACTIONS; DEOXYRIBONUCLEASE I; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY GLOMERULUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MATRIX METALLOPROTEINASES; MICE; MOLECULAR CHAPERONES; MOLECULAR TARGETED THERAPY;

EID: 84945954209     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2015.08.004     Document Type: Review

References (131)

1. Rahman A., Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939.
2. Rekvig O.P., van der Vlag J. The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin Immunopathol 2014, 36:301-311.
3. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
4. Petri M., Orbai A.M., Alarcon G.S., Gordon C., Merrill J.T., Fortin P.R., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012, 64:2677-2686.
5. van Bavel C.C., Fenton K.A., Rekvig O.P., van der Vlag J., Berden J.H. Glomerular targets of nephritogenic autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2008, 58:1892-1899.
6. Rahman A., Hiepe F. Anti-DNA antibodies--overview of assays and clinical correlations. Lupus 2002, 11:770-773.
7. Seredkina N., van der Vlag J., Berden J., Mortensen E., Rekvig O.P. Lupus nephritis: enigmas, conflicting models and an emerging concept. Mol Med 2013, 19:161-169.
8. Jancar S., Sanchez C.M. Immune complex-mediated tissue injury: a multistep paradigm. Trends Immunol 2005, 26:48-55.
9. Ceppellini R., Polli E., Celada F. A DNA-reacting factor in serum of a patient with lupus erythematosus diffusus. Proc Soc Exp Biol Med 1957, 96:572-574.
10. Robbins W.C., Holman H.R., Deicher H., Kunkel H.G. Complement fixation with cell nuclei and DNA in lupus erythematosus. Proc Soc Exp Biol Med 1957, 96:575-579.
11. Seligmann M. [Demonstration in the blood of patients with disseminated lupus erythematosus a substance determining a precipitation reaction with desoxyribonucleic acid]. C R Hebd Seances Acad Sci 1957, 245:243-245.
12. Miescher P., Strassle R. New serological methods for the detection of the L.E. factor. Vox Sang 1957, 2:283-287.
13. Hahn B.H. Antibodies to DNA. N Engl J Med 1998, 338:1359-1368.
14. Rekvig O.P. Anti-dsDNA antibodies as a classification criterion and a diagnostic marker for SLE: critical remarks. Clin Exp Immunol 2015, 179:5-10.
15. Lorenz G., Desai J., Anders H.J. Lupus nephritis: update on mechanisms of systemic autoimmunity and kidney immunopathology. Curr Opin Nephrol Hypertens 2014, 23:211-217.
16. Waldman M., Madaio M.P. Pathogenic autoantibodies in lupus nephritis. Lupus 2005, 14:19-24.
17. Mortensen E.S., Rekvig O.P. Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol 2009, 20:696-704.
18. Kalaaji M., Mortensen E., Jorgensen L., Olsen R., Rekvig O.P. Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells. Am J Pathol 2006, 168:1779-1792.
19. Lafer E.M., Rauch J., Andrzejewski C., Mudd D., Furie B., Furie B., et al. Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids. J Exp Med 1981, 153:897-909.
20. Shoenfeld Y., Rauch J., Massicotte H., Datta S.K., Andre Schwartz J., Stollar B.D., et al. Polyspecificity of monoclonal lupus autoantibodies produced by human-human hybridomas. N Engl J Med 1983, 308:414-420.
21. Carroll P., Stafford D., Schwartz R.S., Stollar B.D. Murine monoclonal anti-DNA autoantibodies bind to endogenous bacteria. J Immunol 1985, 135:1086-1090.
22. Ben-Yehuda A., Rasooly L., Bar-Tana R., Breuer G., Tadmor B., Ulmansky R., et al. The urine of SLE patients contains antibodies that bind to the laminin component of the extracellular matrix. J Autoimmun 1995, 8:279-291.
23. Xie C., Liang Z., Chang S., Mohan C. Use of a novel elution regimen reveals the dominance of polyreactive antinuclear autoantibodies in lupus kidneys. Arthritis Rheum 2003, 48:2343-2352.
24. Amital H., Heilweil M., Ulmansky R., Szafer F., Bar-Tana R., Morel L., et al. Treatment with a laminin-derived peptide suppresses lupus nephritis. J Immunol 2005, 175:5516-5523.
25. Van Bruggen M.C., Kramers C., Hylkema M.N., Smeenk R.J., Berden J.H. Significance of anti-nuclear and anti-extracellular matrix autoantibodies for albuminuria in murine lupus nephritis; a longitudinal study on plasma and glomerular eluates in MRL/l mice. Clin Exp Immunol 1996, 105:132-139.
26. Krishnan M.R., Wang C., Marion T.N. Anti-DNA autoantibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice. Kidney Int 2012, 82:184-192.
27. Mostoslavsky G., Fischel R., Yachimovich N., Yarkoni Y., Rosenmann E., Monestier M., et al. Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry. Eur J Immunol 2001, 31:1221-1227.
28. Yung S., Cheung K.F., Zhang Q., Chan T.M. Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephrol 2010, 21:1912-1927.
29. Sun K.H., Hong C.C., Tang S.J., Sun G.H., Liu W.T., Han S.H., et al. Anti-dsDNA autoantibody cross-reacts with the C-terminal hydrophobic cluster region containing phenylalanines in the acidic ribosomal phosphoprotein P1 to exert a cytostatic effect on the cells. Biochem Biophys Res Commun 1999, 263:334-339.
30. Andre-Schwartz J., Datta S.K., Shoenfeld Y., Isenberg D.A., Stollar B.D., Schwartz R.S. Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. Clin Immunol Immunopathol 1984, 31:261-271.
31. Widom J. A relationship between the helical twist of DNA and the ordered positioning of nucleosomes in all eukaryotic cells. Proc Natl Acad Sci U S A 1992, 89:1095-1099.
32. Griffith J., Bleyman M., Rauch C.A., Kitchin P.A., Englund P.T. Visualization of the bent helix in kinetoplast DNA by electron microscopy. Cell 1986, 46:717-724.
33. Rose N.R., Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993, 14:426-430.
34. Fenton K., Fismen S., Hedberg A., Seredkina N., Fenton C., Mortensen E.S., et al. Anti-dsDNA antibodies promote initiation, and acquired loss of renal Dnase1 promotes progression of lupus nephritis in autoimmune (NZBxNZW)F1 mice. PLoS One 2009, 4:e8474.
35. Seredkina S., Rekvig O.P. Acquired loss of renal nuclease activity is restricted to DNaseI and is an organ-selective feature in murine lupus nephritis. Am J Pathol 2011, 179:1120-1128.
36. Zykova S.N., Tveita A.A., Rekvig O.P. Renal Dnase1 enzyme activity and protein expression is selectively shut down in murine and human membranoproliferative lupus nephritis. PLoS One 2010, 5:8.
37. Thiyagarajan D., Fismen S., Seredkina N., Jacobsen S., Elung-Jensen T., Kamper A.L., et al. Silencing of renal DNaseI in murine lupus nephritis imposes exposure of large chromatin fragments and activation of Toll like receptors and the Clec4e. PLoS One 2012, 7:e34080.
38. Hedberg A., Mortensen E.S., Rekvig O.P. Chromatin as a target antigen in human and murine lupus nephritis. Arthritis Res Ther 2011, 13:214.
39. Tan E.M. Antinuclear antibodies: diagnostic markers and clues to the basis of systemic autoimmunity. Pediatr Infect Dis J 1988, 7(Suppl):S3-S9.
40. Balow J.E., Boumpas D.T., Ausin H.A. Systemic lupus erythematosus and the kidney. Systemic lupus erythematosus 1999, 657-685. Academic Press, San Diego. 3rd ed. R.G. Lahita (Ed.).
41. Shlomchik M.J., Madaio M.P. The role of antibodies and B cells in the pathogenesis of lupus nephritis. Springer Semin Immunopathol 2003, 24:363-375.
42. Van Bruggen M.C., Kramers C., Walgreen B., Elema J.D., Kallenberg C.G., van den Born J., et al. Nucleosomes and histones are present in glomerular deposits in human lupus nephritis. Nephrol Dial Transplant 1997, 12:57-66.
43. Berden J.H., Licht R., Van Bruggen M.C., Tax W.J. Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis. Curr Opin Nephrol Hypertens 1999, 8:299-306.
44. Grootscholten C., Van Bruggen M.C., van der Pijl J.W., Elema J.D., Kallenberg C.G., van den Born J., et al. Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis. Arthritis Rheum 2003, 48:1355-1362.
45. Fismen S., Hedberg A., Fenton K., Jacobsen S., Krarup E., Kamper A., et al. Circulating chromatin-anti-chromatin antibody complexes bind with high affinity to dermo-epidermal structures in murine and human lupus nephritis. Lupus 2009, 18:597-607.
46. Fismen S., Rekvig O.P., Mortensen E. Pathogenesis of SLE dermatitis - a reflection of the process in SLE nephritis?. Curr Rheumatol Rev 2007, 3:1-7.
47. Diamond B., Volpe B.T. A model for lupus brain disease. Immunol Rev 2012, 248:56-67.
48. Faust T.W., Chang E.H., Kowal C., Berlin R., Gazaryan I.G., Bertini E., et al. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci U S A 2010, 107:18569-18574.
49. Huerta P.T., Kowal C., DeGiorgio L.A., Volpe B.T., Diamond B. Immunity and behavior: antibodies alter emotion. Proc Natl Acad Sci U S A 2006, 103:678-683.
50. Appel G.B., Cohen D.J., Pirani C.L., Meltzer J.I., Estes D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987, 83:877-885.
51. Lee S.G., Cho Y.M., So M.W., Kim S.S., Kim Y.G., Lee C.K., et al. ISN/RPS 2003 class II mesangial proliferative lupus nephritis: a comparison between cases that progressed to class III or IV and cases that did not. Rheumatol Int 2012, 32:2459-2464.
52. Tam L.S., Li E.K., Lai F.M., Chan Y.K., Szeto C.C. Mesangial lupus nephritis in Chinese is associated with a high rate of transformation to higher grade nephritis. Lupus 2003, 12:665-671.
53. Berden J.H. Lupus nephritis. Kidney Int 1997, 52:538-558.
54. Marion T.N., Krishnan M.R., Steeves M.A., Desai D.D. Affinity maturation and autoimmunity to DNA. Curr Dir Autoimmun 2003, 6:123-153.
55. Radic M.Z., Weigert M. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu Rev Immunol 1994, 12:487-520.
56. Shlomchik M.J., Marshak-Rothstein A., Wolfowicz C.B., Rothstein T.L., Weigert M.G. The role of clonal selection and somatic mutation in autoimmunity. Nature 1987, 328:805-811.
57. Richmond T.J., Davey C.A. The structure of DNA in the nucleosome core. Nature 2003, 423:145-150.
58. Raz E., Ben Bassat H., Davidi T., Shlomai Z., Eilat D. Cross-reactions of anti-DNA autoantibodies with cell surface proteins. Eur J Immunol 1993, 23:383-390.
59. D'Andrea D.M., Coupaye Gerard B., Kleyman T.R., Foster M.H., Madaio M.P. Lupus autoantibodies interact directly with distinct glomerular and vascular cell surface antigens. Kidney Int 1996, 49:1214-1221.
60. Termaat R.M., Assmann K.J., Dijkman H.B., van Gompel F., Smeenk R.J., Berden J.H. Anti-DNA antibodies can bind to the glomerulus via two distinct mechanisms. Kidney Int 1992, 42:1363-1371.
61. Deocharan B., Qing X., Lichauco J., Putterman C. Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J Immunol 2002, 168:3072-3078.
62. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001, 7:1189-1193.
63. van der Vlag J., Berden J.H. Lupus nephritis: role of antinucleosome autoantibodies. Semin Nephrol 2011, 31:376-389.
64. Kalaaji M., Fenton K.A., Mortensen E.S., Olsen R., Sturfelt G., Alm P., et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 2007, 71:664-672.
65. Mjelle J.E., Kalaaji M., Rekvig O.P. Exposure of chromatin and not high affinity for dsDNA determines the nephritogenic impact of anti-dsDNA antibodies in (NZBxNZW)F1 mice. Autoimmunity 2009, 42:104-111.
66. Comerford F.R., Cohen A.S., Desai R.G. The evolution of the glomerular lesion in NZB mice. A light and electron microscopic study. Lab Invest 1968, 19:643-651.
67. Dillard M.G., Tillman R.L., Sampson C.C. Lupus nephritis. Correlations between the clinical course and presence of electron-dense deposits. Lab Invest 1975, 32:261-269.
68. Ben-Bassat M., Rosenfeld J., Joshua H., Hazaz B., Gura V. Lupus nephritis. Electron-dense and immunofluorescent deposits and their correlation with proteinuria and renal function. Am J Clin Pathol 1979, 72:186-193.
69. Borza D.B., Hudson B.G. Molecular characterization of the target antigens of anti-glomerular basement membrane antibody disease. Springer Semin Immunopathol 2003, 24:345-361.
70. Borza D.B., Neilson E.G., Hudson B.G. Pathogenesis of Goodpasture syndrome: a molecular perspective. Semin Nephrol 2003, 23:522-531.
71. Winfield J.B., Faiferman I., Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest 1977, 59:90-96.
72. Berden J.H., Grootscholten C., Jurgen W.C., van der Vlag J. Lupus nephritis: a nucleosome waste disposal defect?. J Nephrol 2002, 15(Suppl 6):S1-10.
73. Van Bruggen M.C., Kramers C., Berden J.H. Autoimmunity against nucleosomes and lupus nephritis. Ann Med Interne Paris 1996, 147:485-489.
74. Van Bruggen M.C., Walgreen B., Rijke T.P., Tamboer W., Kramers K., Smeenk R.J., et al. Antigen specificity of anti-nuclear antibodies complexed to nucleosomes determines glomerular basement membrane binding in vivo. Eur J Immunol 1997, 27:1564-1569.
75. van Bavel C.C., van der Vlag J., Berden J.H. Glomerular binding of anti-dsDNA autoantibodies: the dispute resolved?. Kidney Int 2007, 71:600-601.
76. Kalaaji M., Sturfelt G., Mjelle J.E., Nossent H., Rekvig O.P. Critical comparative analyses of anti-alpha-actinin and glomerulus-bound antibodies in human and murine lupus nephritis. Arthritis Rheum 2006, 54:914-926.
77. Seredkina N., Zykova S.N., Rekvig O.P. Progression of murine lupus nephritis is linked to acquired renal Dnase1 deficiency and not to up-regulated apoptosis. Am J Pathol 2009, 175:97-106.
78. Tveita A.A., Rekvig O.P., Zykova S.N. Increased glomerular matrix metalloproteinase activity in murine lupus nephritis. Kidney Int 2008, 74:1150-1158.
79. Tveita A., Rekvig O.P., Zykova S.N. Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis. Arthritis Res Ther 2008, 10:229.
80. Fenton K.A., Tommeras B., Marion T.N., Rekvig O.P. Pure anti-dsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice. Autoimmunity 2010, 43:179-188.
81. Frisoni L., McPhie L., Kang S.A., Monestier M., Madaio M., Satoh M., et al. Lack of chromatin and nuclear fragmentation in vivo impairs the production of lupus anti-nuclear antibodies. J Immunol 2007, 179:7959-7966.
82. Kawane K., Nagata S. Nucleases in programmed cell death. Methods Enzymol 2008, 442:271-287.
83. Kawane K., Fukuyama H., Yoshida H., Nagase H., Ohsawa Y., Uchiyama Y., et al. Impaired thymic development in mouse embryos deficient in apoptotic DNA degradation. Nat Immunol 2003, 4:138-144.
84. Kawane K., Ohtani M., Miwa K., Kizawa T., Kanbara Y., Yoshioka Y., et al. Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 2006, 443:998-1002.
85. Napirei M., Karsunky H., Zevnik B., Stephan H., Mannherz H.G., Moroy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 2000, 25:177-181.
86. Krieg A.M., Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 2007, 220:251-269.
87. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25:417-428.
88. Christensen S.R., Shlomchik M.J. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol 2007, 19:11-23.
89. Lim E.J., Lee S.H., Lee J.G., Chin B.R., Bae Y.S., Kim J.R., et al. Toll-like receptor 9 dependent activation of MAPK and NF-kB is required for the CpG ODN-induced matrix metalloproteinase-9 expression. Exp Mol Med 2007, 39:239-245.
90. Merrell M.A., Ilvesaro J.M., Lehtonen N., Sorsa T., Gehrs B., Rosenthal E., et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 2006, 4:437-447.
91. Weening J.J., D'agati V.D., Schwartz M.M., Seshan S.V., Alpers C.E., Appel G.B., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004, 15:241-250.
92. Markowitz G.S., D'agati V.D. Classification of lupus nephritis. Curr Opin Nephrol Hypertens 2009, 18:220-225.
93. Zykova S.N., Seredkina N., Benjaminsen J., Rekvig O.P. Reduced fragmentation of apoptotic chromatin is associated with nephritis in lupus-prone (NZB x NZW)F(1) mice. Arthritis Rheum 2008, 58:813-825.
94. Fismen S., Thiyagarajan D., Seredkina N., Nielsen H., Jacobsen S., Elung-Jensen T., et al. Impact of the tumor necrosis factor receptor-associated protein 1 (Trap1) on renal DNaseI shutdown and on progression of murine and human lupus nephritis. Am J Pathol 2013, 182:688-700.
95. Frost P.G., Lachmann P.J. The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. Clin Exp Immunol 1968, 3:447-455.
96. Yasutomo K., Horiuchi T., Kagami S., Tsukamoto H., Hashimura C., Urushihara M., et al. Mutation of DNase1 in people with systemic lupus erythematosus. Nat Genet 2001, 28:313-314.
97. Tsukumo S., Yasutomo K. DNaseI in pathogenesis of systemic lupus erythematosus. Clin Immunol 2004, 113:14-18.
98. Samejima K., Earnshaw W.C. Trashing the genome: the role of nucleases during apoptosis. Nat Rev Mol Cell Biol 2005, 6:677-688.
99. Oliveri M., Daga A., Cantoni C., Lunardi C., Millo R., Puccetti A. DNase I mediates internucleosomal DNA degradation in human cells undergoing drug-induced apoptosis. Eur J Immunol 2001, 31:743-751.
100. Napirei M., Gultekin A., Kloeckl T., Moroy T., Frostegard J., Mannherz H.G. Systemic lupus-erythematosus: deoxyribonuclease 1 in necrotic chromatin disposal. Int J Biochem Cell Biol 2006, 38:297-306.
101. Ludwig S., Mannherz H.G., Schmitt S., Schaffer M., Zentgraf H., Napirei M. Murine serum deoxyribonuclease 1 (Dnase1) activity partly originates from the liver. Int J Biochem Cell Biol 2009, 41:1079-1093.
102. Napirei M., Ludwig S., Mezrhab J., Klockl T., Mannherz H.G. Murine serum nucleases--contrasting effects of plasmin and heparin on the activities of DNase1 and DNase1-like 3 (DNase1l3). Febs J 2009, 276:1059-1073.
103. Nagata S., Kawane K. Autoinflammation by endogenous DNA. Adv Immunol 2011, 110:139-161.
104. Macanovic M., Sinicropi D., Shak S., Baughman S., Thiru S., Lachmann P.J. The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol 1996, 106:243-252.
105. Macanovic M., Lachmann P.J. Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol 1997, 108:220-226.
106. Verthelyi D., Dybdal N., Elias K.A., Klinman D.M. DNAse treatment does not improve the survival of lupus prone (NZB x NZW)F1 mice. Lupus 1998, 7:223-230.
107. Davis J.C., Manzi S., Yarboro C., Rairie J., Mcinnes I., Averthelyi D., et al. Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus 1999, 8:68-76.
108. Mjelle J.E., Rekvig O.P., Fenton K.A. Nucleosomes possess a high affinity for glomerular laminin and collagen IV and bind nephritogenic antibodies in murine lupus-like nephritis. Ann Rheum Dis 2007, 66:1661-1668.
109. Brenowitz M., Senear D.F., Shea M.A., Ackers G.K. Quantitative DNase footprint titration: a method for studying protein-DNA interactions. Methods Enzymol 1986, 130:132-181.
110. Hsieh M., Brenowitz M. Quantitative kinetics footprinting of protein-DNA association reactions. Methods Enzymol 1996, 274:478-492.
111. Shak S., Capon D.J., Hellmiss R., Marsters S.A., Baker C.L. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A 1990, 87:9188-9192.
112. Mogayzel P.J., Naureckas E.T., Robinson K.A., Mueller G., Hadjiliadis D., Hoag J.B., et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013, 187:680-689.
113. McCarty M. Purification and properties of desoxyribonuclease isolated from beef pancreas. J Gen Physiol 1946, 29:123-139.
114. Mazurkiewicz J., Kepert J.F., Rippe K. On the mechanism of nucleosome assembly by histone chaperone NAP1. J Biol Chem 2006, 281:16462-16472.
115. Kepert J.F., Mazurkiewicz J., Heuvelman G.L., Toth K.F., Rippe K. NAP1 modulates binding of linker histone H1 to chromatin and induces an extended chromatin fiber conformation. J Biol Chem 2005, 280:34063-34072.
116. Banuelos S., Omaetxebarria M.J., Ramos I., Larsen M.R., Arregi I., Jensen O.N., et al. Phosphorylation of both nucleoplasmin domains is required for activation of its chromatin decondensation activity. J Biol Chem 2007, 282:21213-21221.
117. Laskey R.A., Mills A.D., Philpott A., Leno G.H., Dilworth S.M., Dingwall C. The role of nucleoplasmin in chromatin assembly and disassembly. Philos Trans R Soc Lond B Biol Sci 1993, 339:263-269.
118. Zhao R., Davey M., Hsu Y.C., Kaplanek P., Tong A., Parsons A.B., et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 2005, 120:715-727.
119. Zhao R., Houry W.A. Hsp90: a chaperone for protein folding and gene regulation. Biochem Cell Biol 2005, 83:703-710.
120. Rekvig O.P., Hannestad K. The specificity of human autoantibodies that react with both cell nuclei and plasma membranes: the nuclear antigen is present on core mononucleosomes. J Immunol 1979, 123:2673-2681.
121. Villeponteau B. Heparin increases chromatin accessibility by binding the trypsin-sensitive basic residues in histones. Biochem J 1992, 288:953-958.
122. Hedberg A., Fismen S., Fenton K.A., Fenton C., Osterud B., Mortensen E.S., et al. Heparin exerts a dual effect on murine lupus nephritis by enhancing enzymatic chromatin degradation and preventing chromatin binding in glomerular membranes. Arthritis Rheum 2011, 63:1065-1075.
123. Polikanov Y.S., Rubtsov M.A., Studitsky V.M. Biochemical analysis of enhancer-promoter communication in chromatin. Methods 2007, 41:250-258.
124. Conde E Silva, Black B.E., Sivolob A., Filipski J., Cleveland D.W., Prunell A. CENP-A-containing nucleosomes: easier disassembly versus exclusive centromeric localization. J Mol Biol 2007, 370:555-573.
125. Simeonova M., Tchacarov E. Prefixation chromosome banding with heparin. Hum Genet 1980, 56:63-66.
126. Van Bruggen M.C., Walgreen B., Rijke T.P., Corsius M.J., Assmann K.J., Smeenk R.J., et al. Heparin and heparinoids prevent the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice. Kidney Int 1996, 50:1555-1564.
127. Naparstek Y., Ben-Yehuda A., Madaio M.P., Bar-Tana R., Schuger L., Pizov G., et al. Binding of anti-DNA antibodies and inhibition of glomerulonephritis in MRL-lpr/lpr mice by heparin. Arthritis Rheum 1990, 33:1554-1559.
128. Van Bruggen M.C., Kramers C., Hylkema M.N., Smeenk R.J., Berden J.H. Pathophysiology of lupus nephritis: the role of nucleosomes. Neth J Med 1994, 45:273-279.
129. Kramers C., Hylkema M.N., Van Bruggen M.C., van de Lagemaat R., Dijkman H.B., Assmann K.J., et al. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 1994, 94:568-577.
130. Berden J.H. Lupus nephritis: consequence of disturbed removal of apoptotic cells?. Neth J Med 2003, 61:233-238.
131. Nowling T.K., Gilkeson G.S. Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther 2011, 13:250.